- Type 2 diabetes mellitus
- Able to see a usual care provider at least twice a year
- HbA1c of ≤6.5 % and ≤ 10.0%
- Patients with any level of CV risk (at least one of the following):
- History of a major clinical manifestation of coronary artery disease i.e. myocardial infarction, surgical or percutaneous (balloon and/or stent) coronary revascularization procedure, or coronary angiography showing at least one stenosis ≥ 50% in a major epicardial artery or branch vessel.
- Ischemic cerebrovascular disease, including: - History of ischemic stroke; strokes not known to be hemorrhagic will be allowed as part of this criterion; transient ischemic attacks (TIAs) are not included;
- History of carotid arterial disease as documented by ≥50 % stenosis documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography, with or without symptoms of neurologic deficit.
- Atherosclerotic peripheral arterial disease, as documented by objective evidence such as amputation due to vascular disease, current symptoms of intermittent claudication confirmed by an ankle-brachial pressure index or toe brachial pressure index less than 0.9, or history of surgical or percutaneous revascularization procedure.
- A diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.
- Ever been treated with an approved or investigational GLP-1 receptor agonist e.g. BYETTA (exenatide), EQW, VICTOZA (liraglutide), or taspoglutide.
- A planned or anticipated revascularization procedure.
- Pregnancy or planned pregnancy during the trial period.
- End-stage renal disease or an estimated glomerular filtration rate (eGFR) derived from serum creatinine (using the simple MDRD-4 formula) of <30 mL/min/1.73 m2. EQW is cleared through the kidneys.
- A known allergy or intolerance to exenatide.
- A history of gastroparesis. Exenatide slows gastric emptying.
- Personal or family history of medullary thyroid cancer or MEN2 (Multiple Endocrine Neoplasia Type 2.
- A history of pancreatitis.
- A history (≥ 2 episodes) of severe hypoglycemia within 12 months of enrollment.
Please view this document for additional information.